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Hepatobiliary surgery is associated with a substantial risk of
bleeding and thrombotic complications. Given the central
role of the liver in hemostasis, it is not surprising that
hemostatic changes occur during and after partial hepatect-
omy or liver transplantation. Also, preoperative hemostatic
abnormalities are frequently present in patients with the
(end-stage) liver disease.1 Bleeding during partial hepatect-
omy may be largely due to surgical and anatomical factors,
but perioperative changes in the hemostatic systemmay also
contribute.2,3 During liver transplant surgery, the substan-
tially altered hemostatic system may contribute to bleeding,
although surgical and anesthesiological factors and portal
hypertension contribute signiﬁcantly.4,5 The riskof deepvein







Abstract Hepatobiliary surgery is a well-known risk factor for thrombotic complications but
is also associated with substantial perioperative blood loss. Given the central role of
the liver in hemostasis, hepatobiliary surgery is frequently accompanied by complex
changes in the hemostatic system. Increasing knowledge of these changes has
resulted in an improved understanding of the etiology of some of the hemostatic
complications. In the early postoperative period a prolongation of conventional
coagulation test times, such as the prothrombin time, is frequently seen. Together
with a decreased platelet count, this suggests a hypocoagulable state. The concomi-
tant decline of anticoagulant factors and development of a von Willebrand factor/
ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif,
member 13) imbalance, however, suggest a hypercoagulable state, potentially con-
tributing to the risk of thromboembolism. Postoperative thromboprophylaxis should
be initiated early to avoid thrombosis, and intensiﬁed prophylaxis might beneﬁt high-
risk patients. The risk of hemorrhagic complications during hepatobiliary surgery has
diminished over time, mainly due to improved surgical and anesthesiological techni-
ques. However, bleeding can still be profound in individual patients and is difﬁcult to
predict using (global) hemostasis tests. A restrictive transfusion and ﬂuid infusion
policy tomaintain a low central venous pressure is crucial in prevention of perioperative
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even in patients receiving adequate thromboprophylaxis.6 In
liver transplant recipients, thrombotic complications of the
hepatic artery or portal vein may occur, and may directly
compromise graft function and vitality.7,8 Prevention and
treatment of bleeding and thrombosis, therefore, are essen-
tial in themanagement of patients undergoing hepatobiliary
surgery.
In the past decade, clinical and laboratory studies have led
to a better understanding of the status of the hemostatic
system of the patient undergoing hepatobiliary surgery.
These new insights are signiﬁcant to further optimize clinical
management.9,10
In this article, we will provide an overview of the new
insights in hemostatic changes during hepatobiliary surgery.
Also, developments in understanding risk factors and the
possible predictors of hemostatic complications during the
perioperative period of hepatobiliary surgery will be dis-
cussed. Finally, strategies for prevention and treatment of
bleeding and thrombotic complications will be summarized.
Hemostatic Changes during and after
Hepatobiliary Surgery
Patients undergoing hepatobiliary surgery may have an
intact hemostatic system before the procedure, for example,
patients requiring a partial hepatectomy for metastasized
colon cancer, or patients with ametabolic disorder requiring
liver transplantation. However, frequently the hemostatic
function is already substantially compromised, such as pa-
tients with cirrhosis requiring partial hepatectomy or liver
transplantation. The hemostatic changes of patients with
cirrhosis have been reviewed extensively elsewhere.11–13 In
short, despite alterations in routine indices of hemostasis
such as the platelet count and the prothrombin time (PT),
patients with cirrhosis appear to be in hemostatic balance
due to a concomitant decline in pro- and antihemostatic
drivers.13 During hepatobiliary surgery, substantial (addi-
tional) changes in the hemostatic system occur. These are
likely due to a combination of factors. On the one hand, there
is consumption induced by surgical damage and reperfusion
injury during liver transplantation, hemodilution, decreased
or absent synthesis of liver-derived hemostatic components
following partial hepatectomyor during the anhepatic phase
of liver transplantation.14,15 On the other hand, there is a
decreased or absent clearance of activated hemostatic pro-
teins when functional liver volume becomes compro-
mised.14,15 Such changes lead to further abnormalities in
routine diagnostic tests of hemostasis. We will summarize
new insights into the development of hemostatic abnorm-
alities during partial hepatectomy and liver transplantation
below.
Primary Hemostasis
The platelet count decreases during and after partial hepa-
tectomy and liver transplantation, reaching a nadir around
day 3, after which it rapidly increases to supraphysiological
levels.16–18 An imbalance in the von Willebrand factor
(VWF)/ADAMTS13 (a disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13) axis has
been suggested to compensate (in part) for the thrombocy-
topenia of cirrhosis and acute liver failure.19,20 A similar
mechanism likely acts during and after partial hepatectomy
and liver transplantation, as high VWF, low ADAMTS13, and
enhanced VWF-dependent in vitro platelet adhesion have
been observed in plasma samples taken during and after
both procedures.21–23 High levels of VWF likely relate to
endothelial cell activation, whereas decreased ADAMTS13 is
likely due to a combination of hemodilution, consumption,
and decreased hepatic synthesis. The imbalanced VWF/
ADAMTS13 axis may not only compensate for the thrombo-
cytopenia during these procedures but may contribute to
thrombotic risk.24 Indeed, imbalanced VWF/ADAMTS13 has
been shown to be a risk factor for arterial thrombosis in
the general population.25,26 Interestingly, a VWF/ADAMTS13
imbalance also develops during pancreas resection,22
although to a lesser extent as compared with the imbalance
developing during partial hepatectomy, indicating that the
decrease in ADAMTS13 following partial hepatectomy is
only partly related to decreased synthetic capacity of the
remnant liver.
Although the function of the primary hemostatic system
may be much better preserved during hepatobiliary surgery
than suggested by the platelet count, the developing throm-
bocytopenia may affect the outcome. Platelets not only are
critical in hemostasis but also appear to play a role in liver
injury and regeneration. Animal studies have demonstrated
that platelets contribute substantially to liver regeneration
following partial hepatectomy,27–30 although the mechan-
isms involved are incompletely understood.31 In humans, it
has been demonstrated that a low postoperative platelet
count is associated with delayed liver function recovery
after partial hepatectomy, which suggests that platelets
play a critical role in liver regeneration after hepatectomy
also in humans.16,17,32,33 Also, a recent study in living donor
transplant recipients demonstrated that in those recipients
that did not receive intraoperative platelet transfusions, the
intraoperative platelet count was positively associated with
graft regeneration as assessed by graft volume measure-
ments by computed tomography.34
Secondary Hemostasis
During partial hepatectomy and liver transplantation, plasma
levels of coagulation factors and inhibitors decrease, which is
likely related to a combination of hemodilution, consumption,
and defective hepatic synthesis.35,36 In patients with an un-
complicated postoperative course, nadir levels are reached
within 24 hours, and coagulation proteins recover to normal
levels in the ﬁrst postoperative weeks.37,38 The reduction in
levels of procoagulant proteins results in a further prolonga-
tion in the PT, which suggests a hypocoagulable state.38,39 In
some samples taken during a liver transplant, the PT even
becomes immeasurably high.39 However, the reduction in
procoagulants is accompanied by a reduction in natural antic-
oagulant proteins.38,39 As the PT is only sensitive to plasma
levels of procoagulant proteins; the test does not assess the net
effect of concomitant alterations in levels of pro- and
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anticoagulant proteins. In addition, plasma levels of procoa-
gulants appear to recover more quickly as compared with
levels of anticoagulant proteins.40More advanced hemostatic
tests including thrombomodulin-modiﬁed thrombin genera-
tion or thromboelastography, therefore, indicate normo- to
hypercoagulability in these patients, despite prolongations in
the PT.39,41–46 Interestingly, one study has shown that a
hypercoagulable TEG (Haemonetics Corp,Massachusetts, Uni-
ted States) as deﬁned by a shortened r-time developed in as
much as 30% of patients during the anhepatic phase of liver
transplantation.45
Plasma ﬁbrinogen levels decrease during partial hepa-
tectomy and liver transplantation,40,47 and recover over time
to supraphysiological levels.48 In patients with cirrhosis,
plasma ﬁbrinogen has both hypo- and hypercoagulable
features. Speciﬁcally, hypersialation impairs ﬁbrin polymer-
ization and thus delays clot formation.49 However, the
ultimately formed ﬁbrin clot has a decreased permeability
as compared with clots generated from healthy indivi-
duals.50 As ﬁbrin clot permeability is considered the “gold
standard” of ﬁbrin clot quality, we previously concluded that
the ﬁbrin clot of patients with cirrhosis has a net prothrom-
botic nature.47,50 During liver transplantation, the perme-
ability of the plasma clot increases and the quality of ﬁbrin
clot during transplant becomes substantially impaired.51
Fibrin clot structure, to our knowledge, has not been studied
in samples taken during partial hepatectomy.
Fibrinolysis
During partial hepatectomy and liver transplantation,
plasma levels of liver-derived ﬁbrinolytic proteins (i.e., plas-
minogen, antiplasmin, thrombin-activatable ﬁbrinolysis in-
hibitor) decreases, whereas levels of endothelial-derived
ﬁbrinolytic proteins (i.e., tissue-type plasminogen activator
[tPA] and plasminogen activator inhibitor type 1 [PAI-1])
increases.36,52 The net effect of the complex changes in the
ﬁbrinolytic system during and after hepatobiliary surgery is
an intraoperative hyperﬁbrinolytic status in part of the
patients, likely because release of t-PA overwhelms the
circulating and acutely released PAI-1.53,54 Following any
surgery, a temporary hypoﬁbrinolytic state occurs due to a
temporary elevation of PAI-1 (the postoperative ﬁbrinolytic
shutdown).55 Following partial hepatectomy, one study has
shown normalization of plasma ﬁbrinolytic potential at day
1, with a “second wave” of hypoﬁbrinolysis between days 3
and 7.36 Interestingly, a strikingly similar “two wave” hypo-
ﬁbrinolytic statewas observed following pancreas resection,
indicating that the sustained hypoﬁbrinolytic state is at least
in part unrelated to decreased synthetic function of the
liver.36 Following liver transplantation, plasma ﬁbrinolytic
potential slowly normalizes over time.56 Plasma hypoﬁbri-
nolysis thus characterizes the early postoperative period of
hepatobiliary surgery.
Summary of Hemostatic Status during and after
Hepatobiliary Surgery
►Table 1 summarizes changes in thehemostaticsystemduring
and after partial liver resection and liver transplantation.
Maintained hemostatic balance characterizes the hemostatic
function of patients during and after hepatobiliary surgery
despite intraoperativedecreases inplasma levels ofhemostatic
proteins, decreasing platelet count, and increasing PT. Intra-
operatively, the hemostatic balance has distinct hypo- and
hypercoagulable features. Speciﬁcally, hypoﬁbrinogenemia
and hyperﬁbrinolysis impair hemostasis andmight contribute
to bleeding, whereas the VWF/ADAMTS13 imbalance and
increased thrombin generation capacity support hemostasis
and perhaps contribute to thrombosis. Postoperatively,
hepatobiliary surgery is characterized by hypercoagulability,
which includes VWF/ADAMTS13 imbalance, enhanced throm-
bin generating capacity, and sustained hypoﬁbrinolysis.22,36,38
As all these factors have been shown to form a risk
factor for thrombotic events in the general population, it
is fair to hypothesize that the hypercoagulable status
following hepatobiliary surgery may contribute to post-
operative thrombotic events, but formal evidence for this is
lacking.
Hemorrhagic Complications
Bleeding may complicate hepatobiliary surgery. Clinically
relevant bleeding rates vary widely between centers, but
blood loss requiring blood product transfusion is not un-
common. In a published series from our center, one-third of
patients undergoing partial hepatectomy required red blood
cell transfusions,32 and mean red blood cell requirements
during liver transplantationwere eight units.57 Although the
improvements in surgical and anesthesiological techniques
have contributed to a substantial decrease in blood loss and
transfusion requirements over time,4 profound blood loss
may occur in individual patients. The main causes of blood
loss in hepatobiliary surgery consist of surgical and patient-
related factors, which includes altered hemostasis in those
patients with the end-stage liver disease.5 Factors that may
contribute to bleeding during partial hepatectomy include
the quality of liver tissue to be transected, the method
of parenchymal transection, and the central venous pres-
sure.2,3,58,59 In liver transplantation, factors that may con-
tribute to perioperative blood loss are severity and etiology
of liver disease, severity of portal hypertension, nutritional
state, concomitant renal failure, length of the cold ischemia
time, previous surgical procedures, and the type of surgical
technique used (vena cava replacement vs. piggyback
technique).4,60,61
Although blood loss is manageable in the vast majority of
patients by surgical repair and transfusion of blood products,
there are multiple reasons to limit blood loss as much as
possible. Blood loss and blood product requirements have
been dose-dependently linked to adverse outcomes includ-
ing mortality in patients undergoing partial hepatectomy or
liver transplant surgery.4,62 Although mechanisms that may
be involved in deleterious effects of blood product transfu-
sion in patients undergoing hepatobiliary surgery are in-
completely understood, they include general transfusion
reactions including transfusion-related acute lung injury,
which appears more prevalent in patients undergoing
Seminars in Thrombosis & Hemostasis Vol. 43 No. 7/2017
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hepatobiliary surgery as compared with patients transfused
in other contexts.63 Also, transfusion-associated circulatory
overload may contribute to exacerbation of bleeding as it
increases portal hypertension.
Thrombotic Complications
Besides an acquired hypercoagulable state related to hepa-
tobiliary surgery, multiple additional risk factors for post-
operative thrombotic events may be present in these
patients, including (preoperative) cancer, local vascular
abnormalities, local abnormalities in blood ﬂow, presence
of indwelling catheters, and prolonged postoperative
immobilization.64,65
Partial Hepatectomy
Venous thromboembolism (VTE) occurs after partial hepa-
tectomy, with a reported incidence varying from 2.9 to
4.8%.6,64–66 In one of the larger retrospective studies, VTE
was found to be directly proportional to the magnitude of
hepatectomy.64 Major hepatectomy was associated with a
threefold increase in the risk of VTE (1 VTE per 17 patients)
compared with minor hepatectomy (1 VTE per 48
patients).64
Besides deep vein thrombosis and pulmonary embolism,
portal vein thrombosis (PVT,►Fig. 1) is a frequent complica-
tion after hepatectomy, with a reported incidence varying
from 2.1 to 9.1%.67,68 As portal venous ﬂow is an important
determinant of liver regeneration,69–71 it is possible that
reduced portal venous ﬂow due to PVT results in delayed
liver regeneration.
Liver Transplantation
Thrombotic events occurring after liver transplantation can
be divided into local hepatic vessel thrombosis (►Fig. 1) and
systemic thrombotic complications. Hepatic vessel throm-
bosis poses a threat to both patient and graft survival. The
incidence of hepatic artery thrombosis (HAT) is approxi-
mately 3 to 7%.72–75 HAT may occur early (within 2–3
months) after transplantation, but may also occur years
after the procedure.75 Early HAT may result in necrosis of
the bile ducts and eventually graft loss if the arterial ﬂow is
not restored in time.73 In comparison with early HAT, late
HAT might not be life threatening or even have clinical
consequences because of the formation of collateral arterial
circulation before total obstruction.73 Preoperative hyper-
coagulability, assessed by thromboelastography, has been
shown to indicate an increased risk for postoperative HAT.76
In addition, it has been shown that preoperative PVT is a
risk factor for development of postoperative HAT, again
suggesting that a relative hypercoagulable state predisposes
to HAT.77
PVT complicates around 2 to 3.1% of liver transplanta-
tions.7,72,78 Notably, the incidence of preexisting PVT dis-
covered during surgery is considerably higher, 4.9 to 14%,
with an even higher incidence in speciﬁc subgroups, such as
patients with a malignancy.7,79 The risk of PVT after liver
transplantation is related to technical difﬁculties during
surgery, prior PVT, a pediatric recipient, splenectomy, the
use of venous conduits, and small portal vein size.54 Early
postoperative PVT can cause acute clinical deterioration
because of ischemia, ascites, and increased portal vein
pressure.7,54 Early PVT is associated with an increased
Fig. 1 Hepatic vessel thrombosis
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mortality compared with liver transplant recipients who do
not develop a PVT.8,72
Systemic thrombotic complications may occur in the
perioperative period, but also years after transplantation.
Recently, several cohort studies have reported on the overall
incidence of VTE after liver transplantation. These reports
showed incidences varying between 4.5 and 8.6%.80–84 No-
tably, the study that reported an incidence of 8.6% only
considered the number of deep vein thrombosis,82 an even
higher incidence would likely have been found if pulmonary
embolisms had been taken into account. Importantly, none
of the patients in this study received pharmacological
thromboprophylaxis.
Although less common, intraoperative thrombosis is of
signiﬁcant relevance due to the associationwith an increased
morbidity and mortality.45 Intraoperatively, acute intracar-
diac thrombosis or pulmonary embolismmay occur, with an
estimated incidence between 0.4 and 6.2%.85–87 These com-
plications are potentially fatal and appear to be more fre-
quent in liver transplant recipients than in other surgical
patients.88 As previously argued; the current literature
shows that a large proportion of the patients undergoing
liver transplantation develop a hypercoagulable state during
surgery, which may contribute to the development of in-
traoperative or early postoperative thrombotic complica-
tions.45 Intraoperative hypercoagulability was particularly
frequent in patients with cholestatic disease, acute liver
failure, and nonalcoholic steatohepatitis.45
Prevention and Treatment of Bleeding
Hepatic resection is often accompanied by intraoperative
blood loss primarily occurring during parenchymal transec-
tion or tumor resection. Similarly, liver transplantation may
also cause excessive blood loss during surgery, which may
lead to increased postoperative morbidity and mortality.89
There are several approaches available to attempt to reduce
intraoperative blood loss, as will be outlined below.
Central to our strategy to minimize blood loss is a
restrictive ﬂuid infusion policy. Multiple studies have de-
monstrated that maintenance of a low central venous pres-
sure (CVP) and even a preoperative reduction of CVP by
phlebotomy is a beneﬁcial strategy in minimizing blood loss
during hepatectomy or liver transplantation.58,59,90,91 Our
ﬂuid restriction management includes the absence of rou-
tine prophylactic correction of abnormal coagulation tests
(PTor point-of-care). Indeed, routine correction of abnormal
coagulation tests with an infusion of fresh frozen plasma
(FFP) is not effective in reducing intraoperative blood
loss.5,90 Moreover, preoperative coagulation tests have pro-
ven to be very poor predictors of intraoperative bleeding as
reviewed in detail by Larsen et al in this issue.92
Treatment of bleeding during liver surgery traditionally
consists of transfusion of FFP, ﬁbrinogen concentrate or cryo-
precipitate, and platelet concentrates guided by routine diag-
nostic test or point-of-care testing. Transfusion of large
amounts of FFP may, in fact, be counterproductive as it leads
to ﬂuid overload and a subsequent increase in the central and
portal venous pressure, which is already elevated in many
cirrhotic patients. Prothrombin complex concentrate (PCC)
may be used as an alternative to FFP. PCC is a low-volume
plasma product that contains selected procoagulant proteins
and the anticoagulant proteins S and C. The advantage of PCCs
over FFP is the low volume and the potential to fully normalize
factor levels,while thedisadvantage is that PCCsdonot contain
all procoagulant factors. A recent single-center retrospective
study of liver transplant recipients showed that a ROTEM
(Tem InternationalGmbH,Munich,Germany)-basedapproach
to administering PCCs and/or ﬁbrinogen concentrate was
safe and effective as compared with an FFP/platelet concen-
trate-based approach.93 Another low-volume prohemostatic,
recombinant factor VIIa (rFVIIa) has been trialed in liver
transplantation. A meta-analysis on the use of prophylactic
rFVIIa during hepatic surgery, however, did not show efﬁcacy
on perioperative bleeding.94 Although in this meta-analysis
rFVIIa did not showan increase in the risk for thromboembolic
events, the thrombotic risk is of concern.94 Position on the use
of rFVIIa as a possible rescue agent in patientswith intractable
bleeding has yet to be deﬁned.95
Whereas the evidence for the beneﬁts of blood products
in perioperative medicine is low, the supporting evidence for
transfusion-related complications including transfusion asso-
ciated lung injury, transfusion-associated circulatoryoverload,
and infectious complications are increasingly acknowl-
edged.62 As in other types of surgery,96,97 transfusion of blood
products during liver surgery and liver transplantation has
been associatedwith increasedmorbidity andmortality.4 Our
current practice is in general one of wait-and-see approach to
start blood product transfusion only in actively bleeding
patients with evidence of hemostatic abnormalities. Point-
of-care testing by thromboelastography is used to guide blood
product transfusion.
In the past two decades, improvements in surgical tech-
niques have had an important impact in improving outcome
after liver transplantation. Mainly the introduction of the
piggyback technique (liver transplantation with preserva-
tion of the recipient vena cava) resulted in lower blood
transfusion requirements compared with patients trans-
planted using the ‘classical’ technique.98,99
Although the cause of blood loss during liver transplanta-
tion is multifactorial, as noted earlier hyperﬁbrinolysis has
been identiﬁed as an important component of the hemostatic
dysfunction during this procedure. This has provided a scien-
tiﬁc basis for the use of antiﬁbrinolytic drugs, in an attempt to
restore the balance between coagulation and ﬁbrinolysis and
to reduce blood loss. Tranexamic acid and aprotinin have been
shown to reduce blood transfusion requirements by approxi-
mately 30% during liver transplantation by well-designed,
placebo-controlled, randomized trials.100–102 No increased
risk of thromboembolic complications has been shown in
any of the randomized controlled trials.
Prevention and Treatment of Thrombosis
As the hemostatic system following liver surgery is balanced
into a hypercoagulable state, with a corresponding risk of
Seminars in Thrombosis & Hemostasis Vol. 43 No. 7/2017



























thrombotic events, a proactive approach to anticoagulant
management after liver surgery appears warranted. Impor-
tantly, thromboprophylaxis should not be withheld from
patients with a prolonged PT or low platelet count, as these
factors unjustiﬁably suggest a hypocoagulable state and
increased bleeding risk.
Following partial hepatectomy, pharmacological throm-
boprophylaxis has been shown to reduce the incidence of
postoperative VTE.6,64,66,103 However, since the risk of
thrombotic events, is still appreciable even in those patients
receiving optimal thromboprophylaxis, studies on safety and
efﬁcacy of more aggressive thromboprophylactic strategies
appear warranted. Notably, the current clinical practice
appears suboptimal as a recent survey in the United States
showed that although the vast majority of hepatobiliary
surgeons would use thromboprophylaxis, many would delay
heparin administration in patients with thrombocytopenia
or a prolonged PT.104 Also, only 14% of surveyed surgeons
would continue prophylaxis after discharge. Nonetheless,
awareness of the need for adequate postoperative pharma-
cologic thromboprophylaxis is increasing, leading to adapta-
tions in clinical guidelines.105
Similarly, optimal prevention of thrombotic events fol-
lowing liver transplant surgery requires clinical studies.
Whereas we know that a prolonged PT, in this particular
study displayed as an increase in international normalized
ration (INR), following liver transplantation does not protect
from thrombotic disease, it was recently shown that those
patients that developed a venous thrombosis following liver
transplantation had a signiﬁcantly higher INR at day 7 after
transplantation compared with those that did not develop a
thrombotic event.80 These results suggest that delayed
liver function recovery forms a risk for VTE following liver
transplantation, and reinforce the notion that thrombo-
prophylaxis should not be withheld from patients with a
prolonged PT.
In liver transplantation, there is only one study that
reports on the efﬁcacy of pharmacological thromboprophy-
laxis to prevent systemic thrombosis using subcutaneous
unfractionated heparin every 8 hours. The incidence of VTE
in the nonheparin group was 3.5 versus 1% in the treated
group.84 In two other cohorts assessing incidence of VTE
following liver transplantation, numbers on the use of pro-
phylaxis were absent or only given when patients received
anticoagulant treatment before surgery or when an intrao-
perative thrombectomy was performed.80,81
Pharmacological thromboprophylaxis may also help to
prevent early PVTor HAT, but to our knowledge, the effect of
routine thromboprophylaxis on PVT or HAT has never been
assessed in the postliver transplant population. Thrombo-
prophylaxis has been shown to reduce the risk for PVT
following partial hepatectomy,106 suggesting a role for antic-
oagulation in post-transplant hepatic vessel thrombosis.
HAT is traditionally believed to be a surgical complica-
tion,78,107,108 although patient- and graft-related factors
such as prior liver transplantation, prolonged cold ischemic
time, prolonged operating time, low recipient weight, acute
rejection, hemodynamic, infectious and immunological
factors, have also been reported to contribute.74,76,109Never-
theless, there is increasing amounts of data suggesting that
changes in the hemostatic system may contribute to the
development of HAT as well.54,76 Endothelial damage and
activation of the hemostatic system can be the result of
cytomegalovirus infection (CMV). Supported by the reported
association of CMV with an increased risk of HAT,109,110
screening, and early thromboprophylaxis and/or antiviral
treatment should be considered.
Another possibility in the prevention of HAT is treatment
with platelet inhibitors. Two independent studies have shown
a signiﬁcant incidence reduction of HAT by aspirin.111,112 One
of the studies reported a reduction in the overall incidence of
HAT from 4.6 to 3.0%,111 the second study reported an in-
cidence reduction of lateHAT from3.6 to 0.6%.112 Even though
these studies are limited by their retrospective design and
studypopulations areheterogeneous; therewasa clear beneﬁt
of antiplatelet use without an increase in bleeding events. A
further well-designed randomized study to explore safety and
efﬁcacy of aspirin to prevent HATwould be indicated. Next, to
prophylaxis, early detection of HAT via screening with the
regular use of Doppler ultrasound or contrast enhanced ultra-
sound could be considered.73,75,78,113
Conclusion
Laboratory studies and clinical observations have changed the
insights in the hemostatic status during and following hepa-
tobiliary surgery. Whereas conventional hemostasis tests
(platelet count, PT/INR) are suggestive of a perioperative-
bleeding tendency, more advanced hemostatic tests indicate
a balanced hemostasis with hypercoagulable features. The
concept ofmaintenance of hemostatic balancewith hypercoa-
gulable features is reﬂected in the thrombotic risk following
liver surgery. Nevertheless, intraoperative bleeding remains a
concern, and further reﬁnements in hemostatic management
are required to decrease (excessive) blood loss in individual
patients. Our management strategies include avoidance of
prophylactic correction of abnormal hemostasis tests since
they do not predict bleeding events. Blood loss can be mini-
mized through surgical techniques and anesthesiological in-
terventions including a restrictive ﬂuid infusion policy. We
advise to use blood products wisely and preferably only when
active bleeding occurs. The use of blood products should be
guided by conventional hemostasis tests or point-of-care
testing, based on the local experience.
Because of a hypercoagulable postoperative state follow-
ing liver surgery, we suggest initiating pharmacological
thromboprophylaxis with low molecular weight heparin as
soon as possible.We routinely start thromboprophylaxis at 6
hours after surgery unless active bleeding occurs. It is
plausible that a higher dosage of postoperative thrombopro-
phylaxis is needed for speciﬁc patient populations with
increased risk of thrombotic complications. The prevalence
of VTE in hepatobiliary surgery patients, even in those that
receive early thromboprophylaxis, stresses the need for
further research to optimize thromboprophylaxis in these
patients.
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